Pacific Edge Provides Update on Kaiser EMR Integration

PACIFIC EDGE PROVIDES UPDATE ON KAISER EMR INTEGRATION DUNEDIN, New Zealand - Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces it has completed the software development and integration testing on its project to integrate Cxbladder into the Electronic Medical Records (EMR) system of Kaiser Permanente. We are now completing the administrative and review processes to enable the project to go live. Pacific Edge will continue to provide regular updates on our progress on a quarterly basis in our shareholder updates until the project is completed, and any material announcements in accordance with our NZX continuous disclosure obligations. Pacific Edge Chief Executive Dr Peter Meintjes said: "We are excited to have achieved the important technical milestones in the project, which has spanned many teams and many person-hours across the Kaiser system, our team in the US, and our team in New Zealand. "We have significantly de-risked the project and importantly, the Kaiser urologists, innovation group, EMR implementation team and Pacific Edge team continue to share a common goal and a common commitment to completion as soon as feasible." According to Dr Ronald Loo, MD, a urologist with Kaiser Permanente Southern California Permanente Medical Group, the Cxbladder tests have improved access to urology care as Kaiser has emerged from the pandemic with unprecedented demand for services. "The very high negative predictive value of the Cxbladder tests have allowed us to improve access by safely reducing overwhelming demand for screening and surveillance cystoscopy. It's proven to be a quadruple win: convenient and preferred by our members, high quality - reliable results, cost effective for the organization, and a sustainable way to improve the wellbeing of our healthcare teams," Dr Loo said. Kaiser Permanente is the largest integrated healthcare provider in the US, serving 12.6 million members, which equates to approximately 3.7% of the population in the USA. It operates 39 hospitals, more than 700 medical offices, and employs 23,656 physicians and 65,000 nurses. Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer. For more information: Dr Peter Meintjes Chief Executive Pacific Edge P: 022 032 1263 Richard Inder The Project P: 021 645 643 OVERVIEW www.pacificedgedx.com Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA. About Cxbladder www.cxbladder.com Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 2,000 US urologists in the diagnosis and management of more than 80,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 75% of the population via public healthcare and all residents have the option of buying the test online. End CA:00409266 For:PEB Type:GENERAL Time:2023-03-31 08:57:41